Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in Generalized Anxiety Disorder
NCT00731120Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in generalized anxiety disorder (GAD) (3 arms), sponsored by Takeda. Primary endpoint: Hamilton Anxiety Scale Total Score at Week 8. Started Jun 2008; status: completed.
02
Drugs
vortioxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00731120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00731120.